KalVista Pharmaceuticals
KALV | NASDAQ
$27.00
$0.00 (0.00%)
At close: Jun 10, 2026, 4:00 PM ET
KalVista Pharmaceuticals Company Profile
Company profile explainedCompany Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer & Director |
| Bilal Arif | Chief Operating Officer |
| Brian Piekos | Chief Financial Officer |
| Linea Aspesi | Chief People Officer |
| Brian Krex | General Counsel |
| Christopher L. Hamblett | Senior Vice President of Corporate Development |
| Christopher Yea | Chief Development Officer |
| Jarrod Aldom | Vice President of Corporate Communications |
| Paul K. Audhya | Chief Medical Officer |
| Rachel Morten | Senior Vice President of Regulatory Affairs & QA |
| Ryan Baker | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jun 22, 2026 | 15-12G | Filing |
| Jun 16, 2026 | EFFECT | Filing |
| Jun 11, 2026 | S-8 POS | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 4 | Filing |
| Jun 11, 2026 | 4 | Filing |
KalVista Pharmaceuticals
| Country | United States |
| IPO Date | Apr 9, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Benjamin L. Palleiko |
Contact Details
200 Crossing Boulevard Framingham,
Massachusetts 01702 United States
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| SIC Code | 2834 |
Recent News
- 5 months ago / businesswire.comChiesi Group Completes Acquisition of KalVista Pharmaceuticals
- 6 months ago / zacks.comKalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
- 6 months ago / businesswire.comKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
- 7 months ago / businesswire.comKalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
- 7 months ago / seekingalpha.comKalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive
Add to Watchlist
Select watchlists to add or remove KALV